ImmunityBio higher after early-stage trial results for cell therapy in lymphoma

[Lymphoma blood test]

Shares of ImmunityBio (NASDAQ:IBRX [https://seekingalpha.com/symbol/IBRX]) traded higher on Wednesday after the immunotherapy developer disclosed early-stage trial results for its natural killer cell therapy candidate in patients with a form of lymphoma.

Citing early data from its Phase 1 QUILT-106 trial, the company said that the first two patients with late-stage Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkin lymphoma (NHL)—who received its CD19 CAR-NK cell therapy experienced complete responses.

The open-label study is designed to evaluate IBRX's cell therapy in certain types of NHL as a single agent and with rituximab, an antibody medicine marketed by Roche (OTCQX:RHHBY [https://seekingalpha.com/symbol/RHHBY]) and Biogen (BIIB [https://seekingalpha.com/symbol/BIIB]) as Rituxan for lymphoma and other conditions.

One patient developed CR after receiving CD19 CAR-NK cell therapy as a single agent, and the other patient received it in combination with rituximab.

Both were heavily pretreated, but they well tolerated the experimental therapy with no significant toxicities, ImmunityBio (NASDAQ:IBRX [https://seekingalpha.com/symbol/IBRX]) said. The company has recruited a third patient with WM for the study. [https://seekingalpha.com/pr/20199406-immunitybio-reports-complete-responses-in-non-hodgkin-waldenstrom-lymphoma-patients-with]

MORE ON IMMUNITYBIO

* ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval [https://seekingalpha.com/article/4802677-immunitybio-still-flashing-signs-of-life-after-another-anktiva-approval]
* ImmunityBio: High Stakes On Anktiva's Growth Amidst FDA Friction And Financial Pressures [https://seekingalpha.com/article/4800828-immunitybio-high-stakes-on-anktiva-growth-amidst-fda-friction-and-financial-pressures]
* ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze [https://seekingalpha.com/article/4794386-immunitybio-lymphopenia-opportunity-could-provoke-short-squeeze]
* ImmunityBio GAAP EPS of -$0.10 beats by $0.01, revenue of $26.43M beats by $2.38M [https://seekingalpha.com/news/4478287-immunitybio-gaap-eps-of-0_10-beats-by-0_01-revenue-of-26_43m-beats-by-2_38m]
* ImmunityBio secures $80M financing [https://seekingalpha.com/news/4472040-immunitybio-secures-80m-financing]